We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
HealthBox Software is a technology company building products for the post-COVID healthcare landscape. Its first product, ClearPass, was met with success. The tool asks an employee a series of screening questions related to COVID-19, including evidence of fever, fatigue, and dry cough, etc. ClearPass has over 400,000 end-users including companies like Johnson Controls, Remy Cointreau and the San Diego School District. HealthBox aims to be a significant contender in the global digital health market that is expected to be worth $600 billion by 2026. The company is on the verge of launching another innovative product, MyHealthBox. It is a consumer-facing digital health app that will allow users to store their medical records, easily accessible 24/7. HealthBox asserts that the app will have an array of features, including AI health assessment services, dietary advice and data-powered lifestyle guidance. The company will use 47% of the investment towards technology and development costs, and 53% towards sales and marketing.

Pitch Rated

79%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £144,265
Polysolar specialises in manufacturing photovoltaic windows capable of generating electricity, which can be used in buildings to generate clean renewable energy whilst also meeting planning regulations. Its technology is already in-use by major organisations such as Network Rail and Sainsbury's.

Pitch Rated

69%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £1,311,180
Glovebox Direct is an online automotive parts, accessories and merchandise marketplace selling original equipment direct from the car and bike brands.
days to go: Expired investment: £181,670
Advanced Blast & Ballistic Systems (ABBS) is a company that has developed globally patented systems to counteract the forces an armoured vehicle sustains when a mine or Improvised Explosive Device (IED) explodes under it. As per reports, mines and IEDs accounted for over 80% of UK and US army casualties in Iraq & Afghanistan. ABBS believes that its products can keep occupants inside a vehicle completely safe from the aforementioned explosive devices. The armoured vehicle protection market has a value of about $20 billion wherein ABBS aims to be a major contender. The company has received £2 million-plus revenues till date from Research and Development (R&D) grants in the UK, as well as, sold its products to the US Army and Israel with profits worth £145,000 in 2018 and £560,000 in 2019 respectively. It will use the investment to bring its products to more markets globally.

Pitch Rated

78%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £445,814
SpaceX is an aerospace manufacturer and space transportation services company founded in 2002 by Elon Musk that aims to reduce space transportation costs and eventually enable the colonisation of Mars. The company has developed several launch vehicles, rocket engines and Autonomous Spaceport Drone Ship (ASDS) landing platforms. Its project, Falcon 9, became the first rocket to accomplish a propulsive vertical landing in December 2015. As of March 2018, SpaceX had over 100 launches on its manifest representing about $12 billion (£9.24 billion) in contract revenue. The company has also ventured into providing satellite internet access by launching its Starlink project. As of 13th June 2020, it has launched 540 Starlink satellites. It will soon launch its Interplanetary Transport System (ITS), Starship, to further inter-planetary travel and colonisation. They will use the investment to grow its projects across various verticals.
days to go: Expired investment: £8,752,000
Advanced Blast & Ballistic Systems (ABBS) is a company that has developed globally patented systems to counteract the forces an armoured vehicle sustains when a mine or Improvised Explosive Device (IED) explodes under it. ABBS asserts that mines and IEDs accounted for over 80% of UK and US army casualties in Iraq and Afghanistan. ABBS aims to change this and become a major contender in the $20 billion armoured vehicle protection market. The company points out that it has been tasked by the European Union Aviation Safety Agency (EASA) and European Organisation for Civil Aviation Equipment (EUROCAE) to draft safety regulations for emergency descent arrest systems. The company also holds multiple patents for its proven Vehicle Global Acceleration Mitigation (VGAM) vehicle mine protection system and has a patent pending for a Zero-Zero Crash Prevention (ZZCP) system for light aircraft and electric Vertical Takeoff and Landing (eVTOLs) systems. It will use the investment for marketing, boosting R&D, and maintaining and expanding its IP/patent portfolio.
days to go: Expired investment: £88,003
Bioepic is an app which enables users to easily and non-invasively measure their health status in just 30 seconds using just a smartphone. The app calculates pulse wave velocity, body temperature, blood pressure, heart rate variability chaos, vascular stiffness and the effectiveness of inhalers. 
days to go: Expired investment: £12,500
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph